Ageing with HIV

a multidisciplinary review

A. Calcagno, S. Nozza, C. Muss, B. M. Celesia, F. Carli, S. Piconi, G. V. De Socio, A. M. Cattelan, G. Orofino, D. Ripamonti, A. Riva, G. Di Perri

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Introduction: After the introduction of highly active antiretroviral treatment, the course of HIV infection turned into a chronic disease and most of HIV-positive patients will soon be over 50 years old. Material and methods: This paper reviews the multiple aspects that physicians have to face while taking care of HIV-positive ageing patients including the definitions of frailty and the prevalence and risk factors of concomitant diseases. From a therapeutic point of view pharmacokinetic changes and antiretroviral-specific toxicities associated with ageing are discussed; finally therapeutic approaches to frailty are reviewed both in HIV-positive and negative patients. Conclusion and discussion: We conclude by suggesting that the combined use of drugs with the least toxicity potential and the promotion of healthy behaviours (including appropriate nutrition and exercise) might be the best practice for ageing HIV-positive subjects.

Original languageEnglish
Pages (from-to)509-522
Number of pages14
JournalInfection
Volume43
Issue number5
DOIs
Publication statusPublished - May 19 2015

Fingerprint

HIV
Practice Guidelines
HIV Infections
Chronic Disease
Therapeutics
Pharmacokinetics
Exercise
Physicians
Pharmaceutical Preparations

Keywords

  • Ageing
  • Comorbidities
  • Frailty
  • HIV
  • Immune senescence
  • Pharmacokinetics
  • Toxicity

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

Calcagno, A., Nozza, S., Muss, C., Celesia, B. M., Carli, F., Piconi, S., ... Di Perri, G. (2015). Ageing with HIV: a multidisciplinary review. Infection, 43(5), 509-522. https://doi.org/10.1007/s15010-015-0795-5

Ageing with HIV : a multidisciplinary review. / Calcagno, A.; Nozza, S.; Muss, C.; Celesia, B. M.; Carli, F.; Piconi, S.; De Socio, G. V.; Cattelan, A. M.; Orofino, G.; Ripamonti, D.; Riva, A.; Di Perri, G.

In: Infection, Vol. 43, No. 5, 19.05.2015, p. 509-522.

Research output: Contribution to journalArticle

Calcagno, A, Nozza, S, Muss, C, Celesia, BM, Carli, F, Piconi, S, De Socio, GV, Cattelan, AM, Orofino, G, Ripamonti, D, Riva, A & Di Perri, G 2015, 'Ageing with HIV: a multidisciplinary review', Infection, vol. 43, no. 5, pp. 509-522. https://doi.org/10.1007/s15010-015-0795-5
Calcagno A, Nozza S, Muss C, Celesia BM, Carli F, Piconi S et al. Ageing with HIV: a multidisciplinary review. Infection. 2015 May 19;43(5):509-522. https://doi.org/10.1007/s15010-015-0795-5
Calcagno, A. ; Nozza, S. ; Muss, C. ; Celesia, B. M. ; Carli, F. ; Piconi, S. ; De Socio, G. V. ; Cattelan, A. M. ; Orofino, G. ; Ripamonti, D. ; Riva, A. ; Di Perri, G. / Ageing with HIV : a multidisciplinary review. In: Infection. 2015 ; Vol. 43, No. 5. pp. 509-522.
@article{5f0c7bc9dae14637bef4088dc7e82632,
title = "Ageing with HIV: a multidisciplinary review",
abstract = "Introduction: After the introduction of highly active antiretroviral treatment, the course of HIV infection turned into a chronic disease and most of HIV-positive patients will soon be over 50 years old. Material and methods: This paper reviews the multiple aspects that physicians have to face while taking care of HIV-positive ageing patients including the definitions of frailty and the prevalence and risk factors of concomitant diseases. From a therapeutic point of view pharmacokinetic changes and antiretroviral-specific toxicities associated with ageing are discussed; finally therapeutic approaches to frailty are reviewed both in HIV-positive and negative patients. Conclusion and discussion: We conclude by suggesting that the combined use of drugs with the least toxicity potential and the promotion of healthy behaviours (including appropriate nutrition and exercise) might be the best practice for ageing HIV-positive subjects.",
keywords = "Ageing, Comorbidities, Frailty, HIV, Immune senescence, Pharmacokinetics, Toxicity",
author = "A. Calcagno and S. Nozza and C. Muss and Celesia, {B. M.} and F. Carli and S. Piconi and {De Socio}, {G. V.} and Cattelan, {A. M.} and G. Orofino and D. Ripamonti and A. Riva and {Di Perri}, G.",
year = "2015",
month = "5",
day = "19",
doi = "10.1007/s15010-015-0795-5",
language = "English",
volume = "43",
pages = "509--522",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel GmbH",
number = "5",

}

TY - JOUR

T1 - Ageing with HIV

T2 - a multidisciplinary review

AU - Calcagno, A.

AU - Nozza, S.

AU - Muss, C.

AU - Celesia, B. M.

AU - Carli, F.

AU - Piconi, S.

AU - De Socio, G. V.

AU - Cattelan, A. M.

AU - Orofino, G.

AU - Ripamonti, D.

AU - Riva, A.

AU - Di Perri, G.

PY - 2015/5/19

Y1 - 2015/5/19

N2 - Introduction: After the introduction of highly active antiretroviral treatment, the course of HIV infection turned into a chronic disease and most of HIV-positive patients will soon be over 50 years old. Material and methods: This paper reviews the multiple aspects that physicians have to face while taking care of HIV-positive ageing patients including the definitions of frailty and the prevalence and risk factors of concomitant diseases. From a therapeutic point of view pharmacokinetic changes and antiretroviral-specific toxicities associated with ageing are discussed; finally therapeutic approaches to frailty are reviewed both in HIV-positive and negative patients. Conclusion and discussion: We conclude by suggesting that the combined use of drugs with the least toxicity potential and the promotion of healthy behaviours (including appropriate nutrition and exercise) might be the best practice for ageing HIV-positive subjects.

AB - Introduction: After the introduction of highly active antiretroviral treatment, the course of HIV infection turned into a chronic disease and most of HIV-positive patients will soon be over 50 years old. Material and methods: This paper reviews the multiple aspects that physicians have to face while taking care of HIV-positive ageing patients including the definitions of frailty and the prevalence and risk factors of concomitant diseases. From a therapeutic point of view pharmacokinetic changes and antiretroviral-specific toxicities associated with ageing are discussed; finally therapeutic approaches to frailty are reviewed both in HIV-positive and negative patients. Conclusion and discussion: We conclude by suggesting that the combined use of drugs with the least toxicity potential and the promotion of healthy behaviours (including appropriate nutrition and exercise) might be the best practice for ageing HIV-positive subjects.

KW - Ageing

KW - Comorbidities

KW - Frailty

KW - HIV

KW - Immune senescence

KW - Pharmacokinetics

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84942549766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942549766&partnerID=8YFLogxK

U2 - 10.1007/s15010-015-0795-5

DO - 10.1007/s15010-015-0795-5

M3 - Article

VL - 43

SP - 509

EP - 522

JO - Infection

JF - Infection

SN - 0300-8126

IS - 5

ER -